The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1483
December 7, 2015
View Complete Issue         Table of Contents 2019 
Nivolumab (Opdivo) plus Ipilimumab (Yervoy) for Metastatic Melanoma
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Nivolumab (Opdivo) plus Ipilimumab (Yervoy) for Metastatic Melanoma
December 7, 2015 (Issue: 1483)
The FDA has approved the combined use of the programmed death receptor-1 (PD-1) blocking antibody nivolumab (Opdivo) and the anti-CLA-4 antibody ipilimumab (Yervoy) for treatment of BRAF V600 wild-type unresectable or metastatic melanoma. This...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Nivolumab (Opdivo) plus Ipilimumab (Yervoy) for Metastatic Melanoma
Article code: 1483e
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.